We and others have shown that the combination of HDAC and proteasomal pathway inhibitors synergistically induces glioma cell death, suggesting the appeal of combination therapeutics to maximize treatment response [17, 26, 27, 28]. The gene discussed is HDAC9; the disease is central nervous system cancer.